Week 33 (Remission Day 1)
No treatments last week which was week32 of fighting A.L.L.
Bloodwork Results
- Potassium:
- Bilirubin(Liver Function):
- White Blood Cells (WBC 4.0-10.0): 3.40
- Hemoglobin (HGB 11.5-16.0): 11.50
- Platelets (PLT 150-500): 25.00
Transfusions
- Blood: NO
- Platelets: NO
Procedures
- Lumbar Puncture: NO
- BoneMarrow Biopsy: NO
Chemo
- Methotrexate via IV drip (avg __min infusion): NO
- Vincristine via IV drip (avg 5min infusion): NO (he wanted to do a low dose this round but it would make Kate's neuropathy worse so he's holding back for now)
- Pegasparagus via drip (avg infusion): YES
- Cyclosphomine: NO
- Cytarabine: NO
- Rituxan via IV drip (avg 4hour infusion): NO
- Daunorubicin via Syring (avg 5min infusion): NO <--causes hair loss
Dr. Notes
Originally Dr. Yang wanted to administer pegaspargus and a low dose of vincristine but since Kate's neuropathy is pretty bad he said the vincristine would make it worse for sure so he's holding back the vincristine for now.
He is going to have Kate start taking an oral steroid starting tomorrow for a few days
Dr. Yang is also going to increase the milligrams of her lyrica to hopefully give Kate some relief from her painful neuropathy. He (Dr. Yang) mentioned hes hesitant on treatment because there are things that could make the neuropathy worse to the point it might not go away.
Good news is he told Kate that she can and should proudly use the word Remission freely. Kate, at this point, is in remission but the goal word is cured but you can't get to that word until you are in remission so this means Kate is even closer to kicking this cancer's ass.
Dr. Yang is not okay releasing Kate to go back to work yet until he gets her "in maintenance" mode which means she has to be able to get the chemo in maintenance which she just can't do quite yet.
So she has a lot of chemo to still do in order to keep the cancer gone but the doctor is very happy with what he see's in the cancer test results but is still concerned about her platelets and her neuropathy.
2 Comments
Recommended Comments